Atherosclerotic Disease Clinical Trial
— TELARTAOfficial title:
Short Telomere in Patients at High Cardiovascular Risk: a Simple Marker or a Major Determinant of Accelerated Arterial Aging
The prevailing view in telomere epidemiology is that leukocyte telomere length (LTL) is
associated with atherosclerosis and accelerated aging since it serves as a biomarker of the
cumulative burden of inflammation and oxidative stress during adult life. Our recent results
however, indicate that telomere length (TL) is mainly determined at birth and childhood.
Since short telomeres ante cede atherosclerosis, the investigators hypothesize that TL is
not just a simple marker, but a real determinant of arterial aging. That is because TL
reflects cellular repair capacity and a short LTL denotes diminished repair reserves. This
hypothesis cannot be tested by measurements of LTL alone, since this parameter reflects TL
at birth and its age-dependent attrition thereafter. The investigators propose, therefore, a
model that makes it possible to examine different elements of TL dynamics in different
tissues: leukocytes, skeletal muscle, endothelial progenitor cells (EPCs), skin or
subcutaneous fat in patients with or without atherosclerosis.
Our model is based on the following premises, which are derived from observations that TL is
synchronized (equivalent) across somatic tissues/cells of the newborn:
- TL in skeletal muscle mainly reflects TL at birth
- The difference in TL between muscle and leukocytes in adults (approximately 1.5 Kbp)
mainly reflects LTL attrition during the growth period, i.e., childhood/adolescence
- TL in EPCs determines the cell proliferative ability and therefore capacity for vessels
repair during aging.
The general aim of the present project is to examine the links of arterial aging with TL, as
expressed in different tissues, and LTL dynamics, as expressed in the difference between TLs
of muscle and leukocytes.
Status | Recruiting |
Enrollment | 340 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Men and women, aged = 20 years who are admitted for different types of surgery or for pacemaker/ defibrillator implantation and provide informed consent for participating in this study. Exclusion Criteria: Conditions which may impact telomere length: - Patients undergoing surgery for cancer - Patients who had had radiotherapy or chemotherapy. |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
France | AP Hôpitaux de Marseille | Marseille | |
France | Chu Nancy | Nancy |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France | Assistance Publique Hopitaux De Marseille, Institut National de la Santé Et de la Recherche Médicale, France, National Research Agency, France, University of Lorraine |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Measure TL in progenitor cells | up to 3 years | No | |
Primary | Telomere Length (LT) dynamics | TL dynamics: as expressed in the difference between TLs of muscle and leukocytes. | up to 3 years | No |
Secondary | Skin telomere length | up to 3 years | No | |
Secondary | Subcutaneous fat telomere length | up to 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03314818 -
Natural History of Carotid Plaque as Determined by 3D Ultrasound
|
N/A | |
Recruiting |
NCT03480568 -
Alirocumab in Patients on a Stable Dialysis Regimen
|
Phase 3 | |
Completed |
NCT00673985 -
Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study
|
N/A | |
Completed |
NCT00090168 -
Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00738725 -
BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
|
N/A | |
Completed |
NCT00352222 -
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries
|
Phase 3 | |
Completed |
NCT02462005 -
Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter. All Comers Registry.
|
||
Completed |
NCT02546648 -
PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study
|
Phase 3 |